Generate Biomedicines Inc’s (NASDAQ:GENB) Quiet Period Set To Expire Tomorrow

Generate Biomedicines’ (NASDAQ:GENB) quiet period is set to expire on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its IPO on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. During Generate Biomedicines’ quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Ratings Changes

A number of brokerages have commented on GENB. Piper Sandler began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target for the company. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating for the company. Morgan Stanley began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating and a $20.00 price target for the company. Guggenheim assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target for the company. Finally, Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines has an average rating of “Moderate Buy” and an average price target of $25.00.

Generate Biomedicines Price Performance

NASDAQ:GENB opened at $12.10 on Tuesday. Generate Biomedicines has a 1 year low of $11.00 and a 1 year high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.